Meeting
2018 Genitourinary Cancers Symposium
A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.
Authors
Carlo Buonerba
Federico II University, Naples, Italy
Carlo Buonerba , Davide Bosso , Sabino De Placido , Giuseppe di Lorenzo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
2016-005251-25
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS387)
DOI
10.1200/JCO.2018.36.6_suppl.TPS387
Abstract #
TPS387
Poster Bd #
P5
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.
First Author: Carlo Buonerba
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2013 Genitourinary Cancers Symposium
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
First Author: Susan Halabi
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Teresa Alonso Gordoa